BioIVT

Your partner in ELEVATING SCIENCE.

[BioIVT @BioIVT]

In #LiquidBiopsy workflows, variability can happen as early as the blood draw. Venipuncture technique, order of draw, and sample handling, can all influence downstream sensitivity and reproducibility before processing even begins. Learn more: https://t.co/TdX6zFMJkx

[BioIVT @BioIVT]

Join us for an overview of #ProteinDegraders & how they differ from small molecule drugs, including internally generated in vitro #ADME data with key ADME characteristics, common challenges & effective strategies to navigate them: https://t.co/sduaLw4ZmX

[BioIVT @BioIVT]

Heading to #ASMS2026? Don’t miss Nadya Benson presenting poster ThP201: “Peptide drug metabolic stability and degradation pathways in human liver lysosomes using high resolution mass spectrometry”

🗓️Thursday, June 4
🕜10:30 AM – 2:30 PM

#GLP1 #Peptides #ADME #DrugMetabolism

[BioIVT @BioIVT]

Join us for a webinar with Akadeum Life Sciences discussing strategies around donor immune profiles & HLA diversity for accelerating #CellandGeneTherapy development + how gentle, negative-selection isolation translates to scalable manufacturing: https://t.co/7pl4ISdlL7

[BioIVT @BioIVT]

In a new #MeettheExpert interview, our GM of Immune Cells Operations reflects on her journey, why high-quality donor-derived #ImmuneCells are foundational to meaningful research, and how building strong professional relationships can shape a career: https://t.co/s2Cy1k5eqe

[BioIVT @BioIVT]

Dr. Noah outlines how we can make #CellandGeneTherapy scalable, affordable & accessible through collective action from regulators, manufacturers, developers & suppliers by aligning around smarter processes, better infrastructure & human‑centered innovation-https://t.co/UT21z88qGq

[BioIVT @BioIVT]

Sourcing both normal & disease‑state biofluids from a single supplier:
• Reduces vendor complexity
• Aligns quality & documentation standards
• Improves supply consistency across studies
All without requiring changes to existing scientific workflows: https://t.co/WVEgnkl9AZ

[BioIVT @BioIVT]

Our team is at #MPSWorldSummit booth #115 to help you source the high-quality biospecimens critical for #NAMs success. Don’t miss our poster on therapeutic reversal of established steatosis using #siRNA in a long-term hepatic co-culture system on Thurs. at 10:00-11:30am!
#MPS2026

[BioIVT @BioIVT]

Our team is excited to be at #EASLCongress booth E41 in Barcelona. Stop by to discuss your biospecimen or research service needs then make sure to join Dr. Juhasz for the roundtable on "In Vitro and In Vivo Liver Disease Models" on Wednesday at 14:05!

[BioIVT @BioIVT]

#NAMs can produce results that are difficult to interpret or validate when they aren’t built on a foundation of well-characterized, high-quality #biospecimens. See how BioIVT can help you obtain results you can trust: https://t.co/jbtPu8Y8eu

#DrugDiscovery #DrugDevelopment

[BioIVT @BioIVT]

#AlzheimersDisease progresses over time but many #diagnostic approaches rely on single snapshots. Advances in blood-based #biomarkers & longitudinal collections are helping researchers better track progression, treatment response & biomarker dynamics: https://t.co/j0UIIn2kXH

[BioIVT @BioIVT]

2C or not 2C, that is the question… at least when it comes to when you should conduct CYP2C induction studies. One of our experts breaks down why, when & how to conduct CYP2C8, 2C9, and 2C19 induction in our latest #ADME101 video: https://t.co/mi5M4Ybv3e

#ADME #DrugInteractions

[BioIVT @BioIVT]

This 2023 study identified S100b in stroke clots as a potential #biomarker for predicting hemorrhage risk after stroke treatment: https://t.co/5Rf6UNy5du

Explore our CNS specimens, like the tissue used as positive control for S100b expression: https://t.co/OBx0b6yDOj

[BioIVT @BioIVT]

New in-person & online events where you can speak with our experts & see insightful presentations on topics including #LiverDisease models, #GLP1 #Peptide #DrugMetabolism, #ADME for #ProteinDegraders, & more: https://t.co/iwWUlICrxR

[BioIVT @BioIVT]

#ProteinDegraders are opening new doors in #DrugDiscovery. We support this work with high-quality biospecimens, advanced in vitro systems, and scientific expertise to help ensure your data is both relevant and regulatory-ready. https://t.co/R18nAgpnVy

#TargetedProteinDegradation

[BioIVT @BioIVT]

BioIVT supplies both high quality normal human & animal biofluids alongside disease state materials to help teams simplify sourcing while maintaining consistent quality & documentation across studies: https://t.co/eZYaSy4lod

#DrugDevelopment #CDx #LiquidBiopsy

[BioIVT @BioIVT]

Join Courtney Noah, PhD and Bill Lloyd, PhD with Akadeum Life Sciences for a webinar outlining donor profiling strategies and isolation techniques to enable scalable #CellandGeneTherapy manufacturing. Learn more and register: https://t.co/hTKxIuIluh

[BioIVT @BioIVT]

#LiquidBiopsy is transforming cancer monitoring through less invasive, real-time insights. But meaningful liquid biopsy research depends on high-quality, clinically-relevant biospecimens that help researchers separate true signals from noise.

Read more: https://t.co/L8l6TRQFJC

[BioIVT @BioIVT]

#LiquidBiopsy is rapidly evolving beyond early cancer detection alone. And as the field continues to advance, operational confidence is going to be the defining key to shaping clinical action.

Read more: https://t.co/LykTwnWENS

#Biomarkers #CDx #PrecisionMedicine

[BioIVT @BioIVT]

The success of #NAMs depends on the biological materials that serve as their starting materials. In our new blog, we discuss aligning experimental systems with the biology they are intended to represent and the decisions they are meant to inform–read now: https://t.co/zGWM2V2Nf1